{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:26:46Z","timestamp":1787160406646,"version":"build-2736575974"},"reference-count":29,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome that is most commonly treated with etoposide and dexamethasone. This standard of care therapy has improved survival, but \u223c15% of patients still die in the first months after diagnosis, and poor responses prompting salvage therapy are frequent. Thus, identifying patients at risk promptly is likely to improve outcomes. We conducted a multi-institutional, retrospective study of pediatric and young adults treated per HLH-94 or HLH-2004 from 2010 to 2019 to identify patients at risk for early mortality. Biweekly data during the first 100\u00a0days of treatment were analyzed using receiver operating curves to define optimal prognostic indicators and their thresholds. The primary end point was survival to bone marrow transplant (BMT) or \u223c1 year if no BMT was pursued. Eighty-nine patients met the study inclusion criteria. Pre-BMT mortality was 13% (n\u00a0= 12), and overall mortality was 27% (n\u00a0=\u00a024). Laboratory markers measured on day 7 of therapy more efficiently predicted outcomes than did either pretreatment or later assessments. The most potent day 7 unfavorable marker was improvement in soluble CD25 (sCD25) of less than 25% from pretherapy levels. Absolute sCD25 level, platelet count, absolute lymphocyte count, and blood urea nitrogen were also discriminatory markers (area under the curve \u2265 0.7). The presence of \u22653 of these unfavorable markers was strongly associated with pre-BMT mortality (accuracy, 0.93). Thus, serial monitoring of sCD25 and assessment of other early (day 7) response markers optimally predicts prognosis with etoposide-based therapy and may indicate the need for earlier use of alternative, response-adapted therapeutic strategies for HLH.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010546","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T16:11:50Z","timestamp":1698682310000},"page":"7258-7269","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis"],"prefix":"10.1182","volume":"7","author":[{"given":"Bethany","family":"Verkamp","sequence":"first","affiliation":[{"name":"1Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Zoref-Lorenz","sequence":"additional","affiliation":[{"name":"2Hematology Institute, Meir Medical Center, Kfar Saba, Israel"},{"name":"3Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"4Division of Immunobiology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenton","family":"Francisco","sequence":"additional","affiliation":[{"name":"5Department of Pediatrics, Mount Sinai Kravis Children\u2019s Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearce","family":"Kieser","sequence":"additional","affiliation":[{"name":"4Division of Immunobiology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Mack","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Arkansas Children\u2019s Hospital, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tucker","family":"Blackledge","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Arkansas Children\u2019s Hospital, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna","family":"Brik Simon","sequence":"additional","affiliation":[{"name":"3Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"7Department of Pediatric Hematology Oncology, Schneider Children\u2019s Medical Center of Israel, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-5694","authenticated-orcid":false,"given":"Joanne","family":"Yacobovich","sequence":"additional","affiliation":[{"name":"3Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"7Department of Pediatric Hematology Oncology, Schneider Children\u2019s Medical Center of Israel, Petah Tikva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Jordan","sequence":"additional","affiliation":[{"name":"4Division of Immunobiology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH"},{"name":"8Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children\u2019s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,11,30]]},"reference":[{"issue":"15","key":"2023121116231928200_bib1","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2023121116231928200_bib2","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00277-016-2727-6","article-title":"Prognostic factors of early outcome in pediatric hemophagocytic lymphohistiocytosis: an analysis of 116 cases","volume":"95","author":"Bin","year":"2016","journal-title":"Ann Hematol"},{"key":"2023121116231928200_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-041610-134208","article-title":"Familial and acquired hemophagocytic lymphohistiocytosis","volume":"63","author":"Janka","year":"2012","journal-title":"Annu Rev Med"},{"issue":"25","key":"2023121116231928200_bib4","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","article-title":"Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study","volume":"130","author":"Bergsten","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2023121116231928200_bib5","first-page":"197","article-title":"Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society","volume":"10","author":"Aric\u00f2","year":"1996","journal-title":"Leukemia"},{"issue":"1","key":"2023121116231928200_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s13023-020-01515-4","article-title":"Clinical profiles and risk factors of 7-day and 30-day mortality among 160 pediatric patients with hemophagocytic lymphohistiocytosis","volume":"15","author":"Li","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2023121116231928200_bib7","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2023121116231928200_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pbc.24188","article-title":"Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab","volume":"60","author":"Marsh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2023121116231928200_bib9","doi-asserted-by":"crossref","first-page":"e26308","DOI":"10.1002\/pbc.26308","article-title":"Salvage therapy for refractory hemophagocytic lymphohistiocytosis: a review of the published experience","volume":"64","author":"Marsh","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2023121116231928200_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1651-2227.2011.02501.x","article-title":"Risk factors for early death in children with haemophagocytic lymphohistiocytosis","volume":"101","author":"Trottestam","year":"2012","journal-title":"Acta Paediatr"},{"key":"2023121116231928200_bib11","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cyto.2017.03.013","article-title":"Prognostic factors of early death in children with hemophagocytic lymphohistiocytosis","volume":"97","author":"Luo","year":"2017","journal-title":"Cytokine"},{"issue":"1","key":"2023121116231928200_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12887-020-02178-7","article-title":"Treatment outcomes and prognostic factors for non- malignancy associated secondary hemophagocytic lymphohistiocytosis in children","volume":"20","author":"Pan","year":"2020","journal-title":"BMC Pediatr"},{"issue":"6","key":"2023121116231928200_bib13","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1097\/PCC.0000000000000449","article-title":"Prognostic factors and long-term outcome in 52 Turkish children with hemophagocytic lymphohistiocytosis","volume":"16","author":"Kaya","year":"2015","journal-title":"Pediatr Crit Care Med"},{"issue":"3","key":"2023121116231928200_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/08880018.2013.858198","article-title":"Risk factors for early fatal outcomes among children with hemophagocytic lymphohistiocytosis (HLH): a single-institution case-series in Vietnam","volume":"31","author":"Dao","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"key":"2023121116231928200_bib15","doi-asserted-by":"crossref","first-page":"876415","DOI":"10.3389\/fimmu.2022.876415","article-title":"The outcome of induction therapy for EBV-related hemophagocytic lymphohistiocytosis: a model for risk stratification","volume":"13","author":"Cui","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"2023121116231928200_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pbc.22774","article-title":"Rate of decline of ferritin in patients with hemophagocytic lymphohistiocytosis as a prognostic variable for mortality","volume":"56","author":"Lin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2023121116231928200_bib17","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-017-2993-y","article-title":"Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review","volume":"96","author":"Lin","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"2023121116231928200_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40272-019-00367-1","article-title":"Macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in childhood inflammatory disorders: diagnosis and management","volume":"22","author":"Henderson","year":"2020","journal-title":"Paediatr Drugs"},{"issue":"40","key":"2023121116231928200_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.21105\/joss.01317","article-title":"Lifelines: survival analysis in Python","volume":"4","author":"Pilon","year":"2019","journal-title":"J Open Source Softw"},{"issue":"4","key":"2023121116231928200_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/bimj.200410135","article-title":"Estimation of the Youden Index and its associated cutoff point","volume":"47","author":"Fluss","year":"2005","journal-title":"Biom J"},{"issue":"5","key":"2023121116231928200_bib21","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00277-020-03980-0","article-title":"Elevated serum myoglobin levels at hospital admission and the risk of early death among patients with hemophagocytic lymphohistiocytosis: evidence from 155 pediatric patients","volume":"99","author":"Li","year":"2020","journal-title":"Ann Hematol"},{"issue":"7","key":"2023121116231928200_bib22","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/pbc.24980","article-title":"Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group","volume":"61","author":"Kogawa","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"2023121116231928200_bib23","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.3109\/10428194.2011.566394","article-title":"Significance of soluble interleukin-2 receptor in patients with hemophagocytic lymphohistiocytosis","volume":"52","author":"Zhang","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2023121116231928200_bib24","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood.V73.8.2128.2128","article-title":"Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes","volume":"73","author":"Komp","year":"1989","journal-title":"Blood"},{"issue":"12","key":"2023121116231928200_bib25","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1182\/blood.V86.12.4706.bloodjournal86124706","article-title":"Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis","volume":"86","author":"Imashuku","year":"1995","journal-title":"Blood"},{"issue":"5","key":"2023121116231928200_bib26","first-page":"220","article-title":"Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases","volume":"78","author":"Dik","year":"2020","journal-title":"Neth J Med"},{"issue":"3","key":"2023121116231928200_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","article-title":"Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research","volume":"29","author":"Schoettler","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"2023121116231928200_bib28","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10875-020-00789-4","article-title":"Thinking beyond HLH: clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy","volume":"40","author":"Gloude","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"issue":"8","key":"2023121116231928200_bib29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s11255-016-1294-z","article-title":"Hemophagocytic lymphohistiocytosis: an update for nephrologists","volume":"48","author":"Filippone","year":"2016","journal-title":"Int Urol Nephrol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7258\/2176336\/blooda_adv-2023-010546-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/23\/7258\/2176336\/blooda_adv-2023-010546-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T11:46:03Z","timestamp":1702295163000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/23\/7258\/498527\/Early-response-markers-predict-survival-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,30]]},"references-count":29,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2023,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010546","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,30]]}}}